SCHEMBL25002909

SCHEMBL25002909

CCOC(=O)c1cc(-c2ccc(OCC)cc2)ccn1

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
HSP90AA1 P07900 2/20 0.49
MAPT P10636 2/20 0.49
MAPK1 P28482 1/20 0.49
NPC1 O15118 4/20 0.46
MMP2 P08253 1/20 0.46
MMP13 P45452 1/20 0.46
MMP14 P50281 1/20 0.46
CYP1A2 P05177 1/20 0.45
PKM P14618 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MITF O75030 1/20 0.45
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3713517 0.88 NPC1 (0.54) RAB9ASMN1; SMN2MAPTNPC1PKM
SCHEMBL25002910 0.86 FDPS (0.50) RAB9AMAPTNPC1MMP2MMP13
SCHEMBL25002921 0.86 ABL1 (0.50) MAPTMMP2MMP13MMP14
SCHEMBL24572143 0.85 GABRA2 (0.53) RAB9ASMN1; SMN2MAPTMAPK1NPC1
SCHEMBL25002932 0.85 GABRA2 (0.53) RAB9ASMN1; SMN2MAPTNPC1MMP2
SCHEMBL8126380 0.85 CYP1A2 (0.51) RAB9ASMN1; SMN2MAPTMAPK1NPC1
SCHEMBL311880 0.84 CYP1A2 (0.50) RAB9ASMN1; SMN2HSP90AA1MAPTMAPK1
Hydrochloric Acid SCHEMBL8124072 0.84 GABRA2 (0.50) RAB9ASMN1; SMN2MAPTMAPK1NPC1
SCHEMBL15530701 0.83 MMP2 (0.44) RAB9ASMN1; SMN2HSP90AA1MAPTNPC1
SCHEMBL3714078 0.81 SMPD1 (0.51) RAB9ASMN1; SMN2MAPTNPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023010192-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS EUROFARMA LABORATÓRIOS S.A. (BR) 2023-02-09 WO disclosed